Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Open Label, Non-Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immune Function Effects, and Efficacy of Multiple Doses of CP-675,206 in Patients With Advanced Melanoma, and Phase 2, Open Label, Randomized Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Regimens of CP-675,206 in Patients With Advanced Melanoma.

Next Previous
X
Search
Trial Profile

Phase 1 Open Label, Non-Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immune Function Effects, and Efficacy of Multiple Doses of CP-675,206 in Patients With Advanced Melanoma, and Phase 2, Open Label, Randomized Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Regimens of CP-675,206 in Patients With Advanced Melanoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use

    • Most Recent Events

    • 10 Sep 2015 Retrospective analysis of this study and 3 other studies [See CTP700023738, CTP700006688 , study A3671001] were published in the European Journal of Cancer.
    • 05 Jun 2012 Company (AstraZeneca) added as reported by ClinicalTrials.gov.(NCT00086489).
    • 05 Jun 2012 Company (AstraZeneca) added as reported by ClinicalTrials.gov.(NCT00086489).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top